WASHINGTON--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced one-year follow-up data from the landmark HORIZONS-AMI trial demonstrated that Angiomax® (bivalirudin) significantly reduced cardiac-related death by 43 percent (p=0.005), improved overall survival by 31 percent (p=0.029) and reduced major bleeding complications by 39 percent (p< 0.0001) compared to heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) in patients undergoing angioplasty. Angiomax showed an absolute reduction of 1.7 percent in cardiac-related death and 1.4 percent in all-cause death at one year. The findings were presented at a late-breaking session of the 20th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium sponsored by the Cardiovascular Research Foundation (CRF).
